Market Overview

UPDATE: Canaccord Genuity Initiates Vical at Buy on Product Platforms

Related VICL
US Stock Futures Edge Higher Ahead Of Retail Sales, Jobless Claims Data
Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial

Canaccord Genuity initiated its coverage on Vical (NASDAQ: VICL) with a Buy rating and a price target of $7.

Canaccord Genuity noted, "Initiating with a BUY, $7 target based on potential of Allovectin in metastatic melanoma (met mel) and our belief in the long-term value of VICL's CMV franchise. We expect widespread use in patients with unresectable melanoma given its clean safety profile and ease of use. We also see blockbuster potential for the CMV franchise – out licensed TransVax and wholly owned CyMVectin – noting the blockbuster potential given unmet need in a large population. Our $7 target is based in pNPV analysis."

Vical closed at $4.33 on Thursday.

Latest Ratings for VICL

DateFirmActionFromTo
Aug 2013CitigroupMaintainsBuy
Aug 2013Canaccord GenuityDowngradesBuyHold
Aug 2013Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for VICL
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (VICL)

Around the Web, We're Loving...

Get Benzinga's Newsletters